4 ms·
The big difference here is that now we have the added problem of dealing with ACE2 bindings which affect human lungs/liver/heart/pancreas/etc. This is a danger
by thowaway959125 5y ago
The big difference here is that now we have the added problem of dealing with ACE2 bindings which affect human lungs/liver/heart/pancreas/etc.
This is a dangerous difference.
> SARS-CoV recognizes angiotensin-converting enzyme 2 (ACE2) as its receptor, whereas MERS-CoV recognizes dipeptidyl peptidase 4 (DPP4) as its receptor.
https://www.nature.com/articles/s41423-020-0400-4 https://www.nature.com/articles/s41423-020-0400-4
- graeme 5y agoSARS-COV-1 also used ACE2 receptors. In fact your article specifically discusses that, and suggests there was potential to use SARS-COV-1 vaccine development to create SARS-COV-2 vaccines. The ACE2 receptor affinity is not novel.
- thowaway959125 5y agoSort of. Very different without getting into the weeds. https://www.nature.com/articles/s41392-020-0184-0 https://www.nature.com/articles/s41392-020-0184-0